Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor

Molecular Cancer Therapeutics

Volumn 8, Issue 5, 2009, Pages 1137-1147

  Abouantoun, Thamara J ^a   MacDonald, Tobey J ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; PRIORITY JOURNAL; RECEPTOR BLOCKING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEDULLOBLASTOMA; NEOPLASM INVASIVENESS; PIPERAZINES; PTEN PHOSPHOHYDROLASE; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 66849097654     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0889     Document Type: Article

References (32)

1. Packer RJ, Cogen P, Vezina G, Rorke LB. Medulloblastoma: clinical and biologic aspects. Neuro-oncol 1999;1:232-250
2. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999;17:832-845 (Pubitemid 29109313)
3. Johnson DL, McCabe MA, Nicholson HS, et al. Quality of long-term survival in young children with medulloblastoma. J Neurosurg 1994;80:1004-1010 (Pubitemid 24154177)
4. Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma. A Children's Cancer Group study. J Clin Oncol 2001;19:3470-3476 (Pubitemid 32730083)
5. MacDonald TJ, Brown K, LaFleur B, et al. Expression profiling of medulloblastoma. PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001;29:143-152
6. Gilbertson RJ, Clifford SC. PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet 2003;35:197-198 (Pubitemid 37363165)
7. Hoch RV, Soriano P. Roles of PDGF in animal development. Development 2003;130:4769-4784 (Pubitemid 37321862)
8. Yu J, Ustach C, Kim H-RC. Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 2003;36:49-59. (Pubitemid 36836256)
9. Georege D. Targeting PDGF receptors in cancer - rationales and proof of concept clinical trials. Adv Exp Med Biol 2003;532:141-151 (Pubitemid 37176785)
10. Matei D, Emerson RE, Lai YC, et al. Autocrine activation of PDGFRα promotes the progression of ovarian cancer. Oncogene 2006;25:2060-2069
11. Cao R, Bjorndahl MA, Religa P, et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 2004;6:333-345 (Pubitemid 39361435)
12. Nister M, Claesson-Welsh L, Eriksson A, Heldin CH, Westermark B. Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J Biol Chem 1991;266:16755-16763 (Pubitemid 21907863)
13. Chopra A, Brown KM, Rood BR, Packer RJ, Macdonald TJ. The use of gene expression analysis to gain insights into signaling mechanisms of metastatic medulloblastoma. Pediatr Neurosurg 2003;39:68-74. (Pubitemid 36829098)
14. Chilton-Macneill S, Ho M, Hawkins C, Gassas A, Zielenska M, Baruchel S. C-kit expression and mutational analysis in medulloblastoma. Pediatr Dev Pathol 2004;7:493-498 (Pubitemid 40385239)
15. Matei D, Chang D, Meei-Huey J. Imatinib mesylate (imatinib) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor and Akt inactivation. Clin Cancer Res 2004;10:681-690 (Pubitemid 38174008)
16. Kilic T, Alberta JA, Zdunek PR, et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyridine class. Cancer Res 2000;60:5143-5150
17. Bernardi RJ, Lowery AR, Thompson PA, Blaney SM, West JL. Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines. J Neurooncol 2008;86:165-172 (Pubitemid 350263413)
18. MacDonald TJ, Tabrizi P, Shimada H, Zlokovic BV, Laug WE. Detection of brain tumor invasion and micrometastasis in vivo by expression of enhanced green fluorescent protein. Neurosurgery 1998;43:1437-1442 (Pubitemid 28545875)
19. Saito Y, Haendeler J, Hojo Y, Yamamoto K, Berk BC. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol Cell Biol 2001;21:6387-6394 (Pubitemid 32927407)
20. Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, Eberhart CG. c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res 2006;66:673-681 (Pubitemid 43165929)
21. Servidei T, Riccardi A, Sanguinetti M, Dominici C, Riccardi R. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor ST1571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and ST1571-induced Akt activation. J Cell Physiol 2006;208:220-228 (Pubitemid 43849008)
22. McGary EC, Weber K, Mills L, et al. inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor ST1571. Clin Cancer Res 2002;8:3584-3591 (Pubitemid 35340737)
23. Ostman A, Heldi CH. PDGF receptors as targets in tumour treatment. Adv Cancer Res 2007;97:247-274 (Pubitemid 46528991)
24. Thomson S, Petty F, Sujka-Kwok I, Epstein D, Haley JD. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis 2008;25:843-854
25. Li J, Kim YN, Bertics PJ. Platelet-derived growth factor stimulated migration of murine fibroblasts is associated with epidermal growth factor receptor expression and tyrosine phosphorylation. J Biol Chem 2000;275:2951-2958 (Pubitemid 30082072)
26. He H, Levitzki A, Zhu HJ, Walker F, Burgess A, Maruta H. Platelet-derived growth factor requires epidermal growth factor receptor to activate p21-activated kinase family kinases. J Biol Chem 2001;276:26741-26744 (Pubitemid 37410570)
27. Decker SJ, Harris P. Effects of platelet-derived growth factor on phosphorylation of the epidermal growth factor receptor in human skin fibroblast. J Biol Chem 1989;264:9204-9209 (Pubitemid 19157553)
28. Liu P, Ying Y, Ko YG, Anderson RG. Localization of platelet-derived growth factor-stimulated phosphorylation cascade to caveolae. J Biol Chem 1996;271:10299-10303 (Pubitemid 26132521)
29. Mineo C, James GL, Smart EJ, Anderson RG. Localization of epidermal growth factor-stimulated Ras/Raf-1 interaction to caveolae membrane. J Biol Chem 1996;271:11930-11935 (Pubitemid 26157268)
30. Geng L, Shinohara ET, Kim D, et al. ST1571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma. Int J Radiat Oncol Biol Phys 2006;64:263-271 (Pubitemid 41831236)
31. McLaughlin ME, Robson CD, Kieran MW, Jacks T, Pomeroy SL, Cameron S. Marked regression of metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI571, Gleevec): a case report and laboratory investigation. J Pediatr Hematol Oncol 2003;25:644-648 (Pubitemid 36959428)
32. Jayawardena S, Sooriabalan D, Indulkar S, Kim HH, Matin A, Maini A. Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate. Am J Ther 2006;13:458-459 (Pubitemid 44435019)